Lundbeck R&D chief encouraged by migraine results, paving the way for more to follow
”There is still a huge need for migraine treatments. As long as that’s true, we will continue our explorations,” head of R&D Johan Luthman says, as Lundbeck ventures into unexplored territory.
by marketwire, translated by daniel pedersen
Pharmaceutical firm Lundbeck is one step closer to having a new preventive treatment option for migraines – something that’s actually completely new. And now, Lundbeck can continue down this path, says Johan Luthman, the company’s head of R&D.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Analyst: Lundbeck migraine study is "exciting" news
For subscribers
